Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
Official title: Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Run by Tel-Aviv Sourasky Medical Center · NCT07913152 · Data updated 2026-11-12
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Locations | 1 site (Tel Aviv) |
| Status | Recruiting |
| Started | June 17, 2026 |
| Main results expected | November 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07913152 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with an acute cardiovascular condition who are clinically stable, live in the Tel Aviv area, have Wi‑Fi and caregiver support for initial 24 hours, and can use the required technology.
✕Probably not a fit
Patients unable to meet stability, home environment, or technological requirements, or those at high risk of rapid deterioration, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this prospective randomized trial, adults with acute cardiovascular conditions are assigned to Hospital-at-Home care or standard in-hospital care to see if remote monitoring at home provides similar safety and benefits. The study enrolls about 150 participants from Tel Aviv Sourasky Medical Center who have conditions such as acute myocardial infarction, pericarditis, myocarditis, pulmonary embolism, heart failure, or post-procedural cardiac interventions. Remote cardiovascular monitoring and support at home are used to manage therapy, vital signs, and potential complications. Outcomes of safety, efficacy, and healthcare utilization will be compared between groups.
Why it matters
Potential benefit: If successful, patients may experience hospital-level care at home with comparable safety, potential reduced length of stay, and greater comfort.
How similar studies have gone: Prior hospital-at-home programs in other medical areas have shown feasibility, with mixed results; this trial adds cardiovascular-specific data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * Residence in the Tel Aviv area, allowing accessibility of the treating team and a rapid response when required. * Mental capacity to provide informed consent and the ability to understand and follow medical recommendations. * Availability of a family member or caregiver who agrees to remain with the patient during the first 24 hours of Hospital-at-Home care and to be available for periodic assessments as needed. This requirement may be waived at the discretion of the patient and treating physician for highly independent patients. * Suitable home environment with Wi-Fi connectivity to support remote monitoring. * Adequate technological literacy of the patient or caregiver to use the required technology. * Clinically stable and at low risk of rapid deterioration, based on vital signs and initial assessments as determined by the treating physician. * The primary indication for hospitalization is one of the following: acute myocardial infarction, pulmonary embolism, pericarditis/myocarditis, heart failure, following transcatheter valve replacement or repair, following pacemaker or implantable cardioverter-defibrillator implantation,. Disease-Specific Inclusion Criteria In addition to the general inclusion criteria, patients must meet the relevant disease-specific criteria: 1. Acute Myocardial Infarction Acute myocardial infarction with or without ST-segment elevation (STEMI or NSTEMI), treated with primary percutaneous coronary intervention (PCI). The intervention must have been performed in a coronary artery other than the proximal left anterior descending (LAD) artery or left main coronary artery, with TIMI grade III flow at the end of the procedure, no additional critical coronary artery stenoses, an uncomplicated PCI without periprocedural complications, and preserved left ventricular systolic function (LVEF \>45%). 2. Pericarditis/Myocarditis Initial diagnosis of pericarditis or myocarditis, with no more than a mild pericardial effusion and preserved left ventricular systolic function (LVEF ≥50%). 3. Pulmonary Embolism Low-intermediate-risk pulmonary embolism following echocardiographic and CT angiographic (CTA) assessment and treatment with oral or subcutaneous anticoagulation; or intermediate-high-risk pulmonary embolism following successful mechanical thrombectomy, with subsequent improvement in hemodynamic and echocardiographic parameters. 4. Following Transcatheter Valve Replacement or Repair Patients following uncomplicated transcatheter aortic valve replacement (TAVR), or transcatheter edge-to-edge repair (TEER) of the mitral or tricuspid valve, with no clear indication for pacemaker implantation. 5. Heart Failure Newly diagnosed (de novo) heart failure or worsening of pre-existing heart failure, regardless of left ventricular ejection fraction (LVEF), with symptomatic NYHA functional class II-IV heart failure requiring hospitalization. 6. Following Pacemaker or Implantable Cardioverter-Defibrillator Implantation. Exclusion Criteria: * Pregnancy. * Inability to provide informed consent. * Clinically unstable medical condition or significant risk of developing hemodynamic or cardiovascular instability. * Requirement for continuous intravenous infusion of fluids or medications. * Uncontrolled pain. * Active significant non-cardiovascular comorbid condition, including acute ischemic stroke, active bleeding, severe exacerbation of pulmonary disease, or sepsis. * Hemoglobin \<8 g/dL. * Estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73 m². * History of non-adherence to medical treatment or failure to attend follow-up visits. * Residence in a facility that provides on-site medical care, such as a nursing facility. * Significant cognitive impairment interfering with the patient's ability to adhere to treatment or participate in education and self-care. * Inability to obtain peripheral intravenous access, including vascular access requiring ultrasound guidance.
Where it's running
-
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel Recruiting
Study contacts
- Study coordinator: Michal Laufer Perl, MD, MHA
- Email: michallp@tlvmc.gov.il
- Phone: 97236974388
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pre-discharge Flu Vaccine for patients with acute heart problems
This trial tests whether giving an influenza vaccine within 24 hours before hospital discharge helps patients who were treated for acute heart issues stay healthier this season.
-
National surveillance of myocarditis and pericarditis after mRNA COVID-19 vaccination
This study is trying to see how mRNA COVID-19 vaccines might affect heart health by following patients who develop heart inflammation after getting vaccinated.
-
Digital cardiac rehab to help heart attack patients improve function
A digital health–supported cardiac rehabilitation program is being tested to see if it helps people after a heart attack improve fitness and stay engaged with rehab, compared with standard outpatient rehab.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease
In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.
-
Innate Immune Cells and Early Fibrotic Repair After a Heart Attack
This study tests whether specific neutrophil and monocyte patterns are linked to early scar formation after a heart attack in STEMI patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.